Ronald Crystal
Fundador en Xylocor Therapeutics, Inc. .
Fortuna: 16 M $ al 30/04/2024
Cargos activos de Ronald Crystal
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Weill Cornell Medical College | Corporate Officer/Principal | - | - |
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Director/Miembro de la Junta | 01/01/2013 | - |
| Fundador | 01/01/2013 | - |
Historial de carrera de Ronald Crystal
Antiguos cargos conocidos de Ronald Crystal.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| GENVEC INC | Fundador | 02/12/1992 | - |
| LEXEO THERAPEUTICS, INC. | Fundador | 01/02/2017 | - |
Annapurna Therapeutics SAS
 Annapurna Therapeutics SAS BiotechnologyHealth Technology Annapurna Therapeutics SAS operates as a gene therapy company. Its therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure. The company was founded by Pierre Bougneres, Hélène Puccio, Amber Salzman, Patrick Aubourg and Ronald G. Crystal and is headquartered in Paris, France. | Fundador | 23/01/2014 | - |
| Corporate Officer/Principal | - | - |
Estadísticas
Internacional
| Estados Unidos | 5 |
| Francia | 2 |
Operativa
| Founder | 4 |
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| LEXEO THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
Annapurna Therapeutics SAS
Annapurna Therapeutics SAS BiotechnologyHealth Technology Annapurna Therapeutics SAS operates as a gene therapy company. Its therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure. The company was founded by Pierre Bougneres, Hélène Puccio, Amber Salzman, Patrick Aubourg and Ronald G. Crystal and is headquartered in Paris, France. | Health Technology |
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
- Bolsa de valores
- Insiders
- Ronald Crystal
- Experiencia